- Home
- AIP vs AVIR Comparison
AIP vs AVIR Comparison
Compare AIP & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIP
- AVIR
- Stock Information
- Founded
- AIP 2003
- AVIR 2012
- Country
- AIP United States
- AVIR United States
- Employees
- AIP N/A
- AVIR N/A
- Industry
- AIP Semiconductors
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- AIP Technology
- AVIR Health Care
- Exchange
- AIP Nasdaq
- AVIR Nasdaq
- Market Cap
- AIP 277.9M
- AVIR 276.9M
- IPO Year
- AIP 2021
- AVIR 2020
- Fundamental
- Price
- AIP $7.80
- AVIR $3.22
- Analyst Decision
- AIP Strong Buy
- AVIR Hold
- Analyst Count
- AIP 4
- AVIR 1
- Target Price
- AIP $13.00
- AVIR $6.88
- AVG Volume (30 Days)
- AIP 116.2K
- AVIR 175.5K
- Earning Date
- AIP 11-05-2024
- AVIR 11-07-2024
- Dividend Yield
- AIP N/A
- AVIR N/A
- EPS Growth
- AIP N/A
- AVIR N/A
- EPS
- AIP N/A
- AVIR N/A
- Revenue
- AIP $54,739,000.00
- AVIR N/A
- Revenue This Year
- AIP $7.87
- AVIR N/A
- Revenue Next Year
- AIP $19.23
- AVIR N/A
- P/E Ratio
- AIP N/A
- AVIR N/A
- Revenue Growth
- AIP 4.53
- AVIR N/A
- 52 Week Low
- AIP $4.53
- AVIR $2.77
- 52 Week High
- AIP $9.54
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- AIP 52.94
- AVIR 39.98
- Support Level
- AIP $7.97
- AVIR $3.32
- Resistance Level
- AIP $8.58
- AVIR $3.48
- Average True Range (ATR)
- AIP 0.44
- AVIR 0.14
- MACD
- AIP 0.07
- AVIR -0.01
- Stochastic Oscillator
- AIP 54.59
- AVIR 9.09
About AIP Arteris Inc.
Arteris Inc is a developer of on-chip interconnect fabric technology designed for a variety of devices and in the development and distribution of Network-on-Chip (NoC) interconnect intellectual property (IP). The company's technology is used in System-on-Chip (SoC) and provides software and services to automate SoC integration, enabling users to efficiently deploy NoC IP, and offer IP support, maintenance services, professional services, and training and on-site support services. The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum profit from Asia Pacific.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).